Soltanieh Samira, Salavatizadeh Marieh, Gaman Mihnea-Alexandru, Kord Varkaneh Hamed, Tan Shing Cheng, Prabahar Kousalya, Lozovanu Oana Deliu, Santos Heitor O, Hekmatdoost Azita
Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology Shahid Beheshti University of Medical Sciences Tehran Iran.
Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania & Department of Hematology, Centre of Hematology and Bone Marrow Transplantation Fundeni Clinical Institute Bucharest Romania.
Food Sci Nutr. 2024 Apr 8;12(7):4581-4593. doi: 10.1002/fsn3.4146. eCollection 2024 Jul.
Hepcidin has a crucial role in iron homeostasis upon inflammatory conditions such as inflammatory bowel disease (IBD). Thus, we conducted a systematic review and meta-analysis to determine the overall association between serum hepcidin concentrations and IBD. Based on the preferred reporting items for systematic review and meta-analysis (PRISMA) protocols, an electronic literature search was conducted on PubMed/MEDLINE, Scopus, and Web of Science until June 2020. Studies were deemed eligible for inclusion if they met the following criteria: (1) diagnosis of IBD, (2) observational design, and (3) measured serum hepcidin and prohepcidin concentrations in IBD patients and control group. Overall, 10 studies including 1184 participants were evaluated. Random-effects meta-analysis revealed that subjects with IBD had 7.22 ng/mL (95% CI: 2.10, 12.34; = .006) higher serum hepcidin concentrations compared to control groups. A nonsignificantly lower serum prohepcidin concentration (0.522 ng/mL, 95% CI: -1.983 to 0.939; = .484) was found for IBD patients compared to healthy subjects. However, there was significant heterogeneity among the studies regarding both hepcidin ( = 98%, < .001) and prohepcidin levels ( = 96%, < .001), respectively. In an age-based subgroup analysis, patients aged ≥18 years with IBD displayed higher serum hepcidin levels when compared to healthy individuals (22.36 ng/mL, 95% CI, 2.12-42.61; .030). Hepcidin concentrations are elevated in subjects with IBD; however, the clinical relevance of this finding requires further evaluation in future investigations as the increase is relatively small compared to the wide range of normal hepcidin values.
在诸如炎症性肠病（IBD）等炎症状态下，铁调素在铁稳态中起着关键作用。因此，我们进行了一项系统评价和荟萃分析，以确定血清铁调素浓度与IBD之间的总体关联。根据系统评价和荟萃分析的首选报告项目（PRISMA）方案，截至2020年6月，在PubMed/MEDLINE、Scopus和Web of Science上进行了电子文献检索。如果研究符合以下标准，则被认为有资格纳入：（1）IBD诊断；（2）观察性设计；（3）测量IBD患者和对照组的血清铁调素和前铁调素浓度。总体而言，对包括1184名参与者的10项研究进行了评估。随机效应荟萃分析显示，与对照组相比，IBD患者的血清铁调素浓度高7.22 ng/mL（95%CI：2.10，12.34；P = 0.006）。与健康受试者相比，IBD患者的血清前铁调素浓度无显著降低（0.522 ng/mL，95%CI：-1.983至0.939；P = 0.484）。然而，关于铁调素（I2 = 98%，P < 0.001）和前铁调素水平（I2 = 96%，P < 0.001）的研究之间分别存在显著异质性。在基于年龄的亚组分析中，年龄≥18岁的IBD患者与健康个体相比，血清铁调素水平更高（22.36 ng/mL，95%CI，2.12 - 42.61；P = 0.030）。IBD患者的铁调素浓度升高；然而，这一发现的临床相关性需要在未来的研究中进一步评估，因为与正常铁调素值的广泛范围相比，升高幅度相对较小。
